NASDAQ
Evaxion Biotech A/S (EVAX) has a price/sales ratio of 4.06x as of Friday, May 22, 2026. This represents a 94.96% decrease compared to its 12-month average of 80.57x. The price-to-sales ratio evaluates a company's stock price relative to its revenue, useful for valuing companies with little or no earnings.
No price data available for this timeframe.